Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada

Overview

Journal Curr Oncol

Publisher MDPI

Date 2025 Jan 24

PMID 39851929

Authors

Lara Chayab

Natasha B Leighl

Mina Tadrous

Christine M Warren

William W L Wong

Affiliations

Soon will be listed here.

Abstract

The treatment landscape for patients with advanced ALK-positive NSCLC has rapidly evolved following the approval of several ALK TKIs in Canada. However, public funding of ALK TKIs is mostly limited to the first line treatment setting. Using linked provincial health administrative databases, we examined real-world outcomes of patients with advanced ALK-positive NSCLC receiving ALK TKIs in Ontario between 1 January 2012 and 31 December 2021. Demographic, clinical characteristics and treatment patterns were summarized using descriptive statistics. Kaplan-Meier analysis was performed to evaluate progression-free survival (PFS) and overall survival (OS) among the treatment groups. A total of 413 patients were identified. Patients were administered alectinib (n = 154), crizotinib (n = 80), or palliative-intent chemotherapy (n = 55) in the first-line treatment. There was a significant difference in first-line PFS between the treatment groups. The median PFS (mPFS) was not reached for alectinib (95% CI, 568 days-not reached), compared to 8.2 months (95% CI, 171-294 days) for crizotinib (HR = 0.34, < 0.0001) and 2.4 months (95% CI, 65-100 days) for chemotherapy (HR = 0.14, < 0.0001). There was no significant difference in first-line OS between the treatment groups. In patients who received more than one line of treatment, there was a significant difference in mOS between patients who received two or more lines of ALK TKIs compared to those who received one line of ALK TKI (mOS = 55 months (95% CI, 400-987 days) and 26 months (95% CI, 1448-2644 days), respectively, HR = 4.64, < 0.0001). This study confirms the effectiveness of ALK TKIs in real-world practice and supports the potential benefit of multiple lines of ALK TKI on overall survival in patients with ALK-positive NSCLC.

References

Khan M, Lin J, Liao G, Tian Y, Liang Y, Li R . ALK Inhibitors in the Treatment of ALK Positive NSCLC. Front Oncol. 2019; 8:557. PMC: 6333640. DOI: 10.3389/fonc.2018.00557. View

Mok T, Camidge D, Gadgeel S, Rosell R, Dziadziuszko R, Kim D . Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020; 31(8):1056-1064. DOI: 10.1016/j.annonc.2020.04.478. View

Weymann D, Dragojlovic N, Pollard S, Regier D . Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges. J Community Genet. 2019; 13(5):467-476. PMC: 9530078. DOI: 10.1007/s12687-019-00428-5. View

Novello S, Mazieres J, Oh I, De Castro J, Migliorino M, Helland A . Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018; 29(6):1409-1416. PMC: 6005013. DOI: 10.1093/annonc/mdy121. View

Ito K, Hataji O, Kobayashi H, Fujiwara A, Yoshida M, DAlessandro-Gabazza C . Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study. J Thorac Oncol. 2016; 12(2):390-396. DOI: 10.1016/j.jtho.2016.07.022. View

Kim D, Tiseo M, Ahn M, Reckamp K, Hansen K, Kim S . Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 35(22):2490-2498. DOI: 10.1200/JCO.2016.71.5904. View

Blackadar C . Historical review of the causes of cancer. World J Clin Oncol. 2016; 7(1):54-86. PMC: 4734938. DOI: 10.5306/wjco.v7.i1.54. View

Hida T, Nokihara H, Kondo M, Kim Y, Azuma K, Seto T . Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017; 390(10089):29-39. DOI: 10.1016/S0140-6736(17)30565-2. View

Cui S, Zhao Y, Dong L, Gu A, Xiong L, Qian J . Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients. Cancer Med. 2016; 5(6):1013-21. PMC: 4924358. DOI: 10.1002/cam4.659. View

10.

Shaw A, Kim T, Crino L, Gridelli C, Kiura K, Liu G . Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017; 18(7):874-886. DOI: 10.1016/S1470-2045(17)30339-X. View

11.

Gibson A, Box A, Dean M, Elegbede A, Hao D, Sangha R . Retrospective Real-World Outcomes for Patients With -Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2021; 2(4):100157. PMC: 8474209. DOI: 10.1016/j.jtocrr.2021.100157. View

12.

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

13.

Huber R, Hansen K, Paz-Ares Rodriguez L, West H, Reckamp K, Leighl N . Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2019; 15(3):404-415. DOI: 10.1016/j.jtho.2019.11.004. View

14.

Sheffield B, Eaton K, Emond B, Lafeuille M, Hilts A, Lefebvre P . Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices. Curr Oncol. 2023; 30(2):2348-2365. PMC: 9955559. DOI: 10.3390/curroncol30020180. View

15.

Ahmed J, Torrado C, Chelariu A, Kim S, Rodon Ahnert J . Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine. JCO Precis Oncol. 2024; 8:e2400038. PMC: 11371109. DOI: 10.1200/PO.24.00038. View

16.

Cheung C, Garratt J, Won J, Cutz J, Gilks B, Tsao M . Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada: Canadian Immunohistochemistry Quality Control Challenges and Successes. Appl Immunohistochem Mol Morphol. 2015; 23(10):677-81. DOI: 10.1097/PAI.0000000000000267. View

17.

Levy A, OBrien B, Sellors C, Grootendorst P, Willison D . Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003; 10(2):67-71. View

18.

Kim D, Mehra R, Tan D, Felip E, Chow L, Camidge D . Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016; 17(4):452-463. PMC: 5063047. DOI: 10.1016/S1470-2045(15)00614-2. View

19.

Camidge D, Kim H, Ahn M, Yang J, Han J, Hochmair M . Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020; 38(31):3592-3603. PMC: 7605398. DOI: 10.1200/JCO.20.00505. View

20.

Collins R, Bowman L, Landray M, Peto R . The Magic of Randomization versus the Myth of Real-World Evidence. N Engl J Med. 2020; 382(7):674-678. DOI: 10.1056/NEJMsb1901642. View